Division of General Internal Medicine, Nephrology, and Rheumatology, Department of Medicine D, University Hospital Münster, Münster, Germany.
Institute of Physiology II, University Hospital Münster, Münster, Germany.
Thromb Haemost. 2019 Nov;119(11):1827-1838. doi: 10.1055/s-0039-1695768. Epub 2019 Sep 7.
The endothelial glycocalyx (eGC), a carbohydrate-rich layer lining the luminal surface of the endothelium, provides a first vasoprotective barrier against vascular leakage in sepsis. We hypothesized that angiopoietin-2 (Angpt-2), antagonist of the endothelium-stabilizing receptor Tie2, induces a rapid loss of the eGC in human sepsis. Using intravital microscopy, we measured the perfused boundary region (PBR), an inverse parameter of eGC dimensions in sublingual microvessels, in patients with sepsis and age-matched nonseptic subjects. Median PBR values were significantly higher in patients compared with controls and correlated with serum Angpt-2 levels. To transfer and further explore these findings in a cell culture system, we exposed endothelial cells (ECs) to serum (5%) from a subgroup of septic patients and nonseptic controls. Confocal and atomic force microscopy revealed that sepsis serum, but not control serum, induced thinning of the eGC on human ECs in vitro, which correlated with paired PBR values obtained in vivo ( = 0.96, < 0.01). Inhibition of Angpt-2 or Tie2 activation completely abolished eGC damage. Mechanistically, sepsis-induced eGC breakdown required the loss of its main constituent heparan sulfate; a result of heparan sulfate-specific enzyme heparanase, which was suppressed by Tie2 activation. Finally, Tie2 activation, but not Angpt-2 inhibition, initiated after septic or enzymatic damage provoked rapid refurbishment of the eGC. Our data indicate that eGC breakdown in human sepsis is mediated via Tie2 deactivation by Angpt-2. Activation of Tie2 seems to accelerate recovery of the eGC and might hold promise as a therapeutic target in human sepsis.
内皮糖萼(eGC)是富含碳水化合物的层,排列在内皮的腔面,提供了针对败血症中血管渗漏的第一道血管保护屏障。我们假设血管生成素-2(Angpt-2),内皮稳定受体 Tie2 的拮抗剂,会导致人类败血症中 eGC 的迅速丧失。我们使用活体显微镜测量了舌下微血管的灌注边界区(PBR),这是 eGC 尺寸的逆参数,在败血症患者和年龄匹配的非败血症患者中。与对照组相比,患者的中位数 PBR 值明显更高,并且与血清 Angpt-2 水平相关。为了在细胞培养系统中转移和进一步探索这些发现,我们将内皮细胞(EC)暴露于败血症患者和非败血症对照组亚组的血清(5%)中。共聚焦和原子力显微镜显示,败血症血清,但不是对照血清,在体外诱导 eGC 在人 EC 上变薄,这与体内获得的配对 PBR 值相关(=0.96,<0.01)。Angpt-2 或 Tie2 激活的抑制完全消除了 eGC 的损伤。从机制上讲,败血症诱导的 eGC 破坏需要其主要成分肝素硫酸酯的丧失;这是肝素硫酸酯特异性酶肝素酶的结果,而 Tie2 激活抑制了肝素酶。最后,Tie2 的激活,而不是 Angpt-2 的抑制,在败血症或酶促损伤后引发 eGC 的快速修复。我们的数据表明,人类败血症中的 eGC 破坏是通过 Angpt-2 使 Tie2 失活介导的。Tie2 的激活似乎可以加速 eGC 的恢复,并且可能作为人类败血症的治疗靶点有一定的前景。